Inozyme Pharma, Inc.
INZY
$1.62
$0.4133.88%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -27.07M | -24.57M | -27.03M | -23.35M | -21.54M |
| Total Depreciation and Amortization | 177.00K | 195.00K | 188.00K | 182.00K | 209.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.89M | 1.77M | 1.03M | -28.00K | -77.00K |
| Change in Net Operating Assets | 5.82M | -1.92M | 2.16M | -1.34M | 2.93M |
| Cash from Operations | -19.19M | -24.53M | -23.66M | -24.53M | -18.49M |
| Capital Expenditure | -17.00K | -13.00K | 0.00 | -32.00K | -105.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.46M | 23.36M | 17.82M | 10.43M | -6.37M |
| Cash from Investing | 15.44M | 23.35M | 17.82M | 10.39M | -6.47M |
| Total Debt Issued | -- | -- | -- | -- | 12.50M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 258.00K | 10.52M | 458.00K | 159.00K | 16.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 258.00K | 10.52M | 458.00K | 159.00K | 12.52M |
| Foreign Exchange rate Adjustments | -4.00K | -1.00K | -1.00K | 10.00K | 134.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.49M | 9.34M | -5.39M | -13.97M | -12.31M |